Lead Product(s) : Palbociclib
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Paleno™ (palbociclib) is a cyclin-dependent kinase inhibitor (key regulators of cell growth) selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties.
Product Name : Paleno
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 01, 2023
Lead Product(s) : Palbociclib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lenalidomide
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Sun Pharma Announces US FDA Approval for Generic Lenalidomide Capsules
Details : Lenalidomide modulates the substrate specificity of CRL4CRBN E3 ubiquitin ligase. Subsequent proteasomal degradation of these transcription factors kills multiple myeloma cells.
Product Name : Revlimid-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 03, 2023
Lead Product(s) : Lenalidomide
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sonidegib Phosphate
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ODOMZO (sonidegib) works by inhibiting a molecular pathway, known as the hedgehog signaling pathway, which is indicated for the treatment of adult patients with locally advanced basal cell carcinoma.
Product Name : Odomzo
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 06, 2020
Lead Product(s) : Sonidegib Phosphate
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
